Lophius Biosciences appoints co-CEO to drive growth
This article was originally published in Clinica
Executive Summary
Lophius Biosciences, a specialist in T cell-based research tools and diagnostics for functional assessment of pathogen/disease-reactive T cells, has appointed Bernd Merkl co-CEO. He was formerly the site and product management leader of Thermo Fisher Scientific’s GeneArt Centre of Excellence for Synthetic Biology. Working alongside Regensburg, Germany-based Lophius’ current CEO, Robert Phelps, Merkl will focus on the commercial operations including all marketing and sales activities. Lophius’ flagship product is T-Track CMV, a diagnostic system intended to determine the functionality of the cell-mediated immune response in cytomegalovirus seropositive transplant patients who undergo an immunosuppressive therapy.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.